Semaglutide Side Effects in Women: A Complete 2026 Guide

Semaglutide side effects in women span a wider clinical picture than the male-dominant trial summaries suggest. While the FDA labels for Ozempic and Wegovy list the same gastrointestinal symptoms regardless of sex, real-world prescribing has surfaced patterns women report more often — cycle changes, hair shedding, lean-mass loss, and oral contraceptive concerns tied to delayed gastric emptying. This guide walks through what the STEP trials¹ and FDA labels²,³ actually document, what is being seen in post-marketing pharmacovigilance, and which symptoms warrant a same-week call to a clinician versus a routine follow-up.

Key facts at a glance

• About 74% of participants in STEP 1 reported at least one GI side effect on semaglutide 2.4mg versus 47% on placebo¹.
• Nausea (44%), diarrhea (32%), vomiting (24%), and constipation (24%) are the most common reactions in Wegovy's label².
• Hair shedding affected ~3% of semaglutide participants vs 1% on placebo in STEP 1¹.
• Semaglutide is contraindicated in pregnancy and carries a boxed warning for medullary thyroid carcinoma².

What semaglutide side effects do women experience most often?

The dominant pattern is gastrointestinal. In STEP 1, the pivotal 68-week trial of semaglutide 2.4mg for weight management, 74.2% of the semaglutide arm reported GI adverse events compared with 47.9% on placebo¹. Nausea led the list at 44%, followed by diarrhea (32%), vomiting (25%), and constipation (24%)². A 2023 JAMA pharmacoepidemiology analysis of >16 million prescriptions found semaglutide users had a ~9x higher risk of pancreatitis, ~4x higher risk of bowel obstruction, and ~4x higher risk of gastroparesis compared with bupropion-naltrexone users⁴.

Women appear to report nausea and vomiting at higher rates than men in post-marketing data, likely reflecting both lower average body weight (higher mg/kg exposure at fixed doses) and known sex differences in gastric emptying. Most GI symptoms are mild-to-moderate and improve as the dose titrates from 0.25mg weekly up to maintenance over 16-20 weeks².

Female-specific patterns: cycles, hair, bone, and lean mass

The FDA label does not list menstrual irregularities, but case reports and patient surveys consistently describe shifts in cycle length, flow volume, and PMS severity once weight loss exceeds ~5-10% of baseline. The plausible mechanism is rapid reduction in adipose-tissue aromatase activity, which lowers peripheral estrogen production and raises sex hormone-binding globulin (SHBG) — the same pattern documented after bariatric surgery⁸.

Hair shedding (telogen effluvium)

In STEP 1, 3.0% of semaglutide-treated participants reported alopecia versus 1.0% on placebo¹. The shedding is typically diffuse, peaks 3-4 months after weight loss accelerates, and resolves once weight stabilizes. It is a classic telogen effluvium pattern driven by rapid caloric deficit rather than a direct drug effect.

Lean mass and bone

Approximately 25-40% of total weight loss on semaglutide 2.4mg is lean body mass in published DEXA sub-studies⁵. For perimenopausal women already losing ~1% bone density per year, accelerated lean-mass loss raises sarcopenia and fall-risk concerns that NAMS recommends addressing with resistance training and adequate protein intake (1.2-1.6 g/kg/day)⁸.

Treatment context: how clinicians manage side effects

Common clinician-led approaches to managing semaglutide side effects include slower titration (extending each dose step beyond 4 weeks), splitting meals into smaller portions, avoiding high-fat triggers for nausea, and adding ondansetron 4mg PRN for breakthrough symptoms. For constipation, increased fiber (25-30g/day), hydration, and osmotic laxatives like polyethylene glycol are standard. None of this constitutes a personal recommendation — dose adjustments, medication changes, and adjunctive prescriptions should be discussed with the prescribing clinician.

For oral contraceptive users, the Wegovy label explicitly states clinically relevant reduction in OC absorption is not expected². However, vomiting within 3-4 hours of an oral contraceptive dose can reduce efficacy regardless of GLP-1 use, so backup contraception during titration weeks is a frequent clinician recommendation. Women planning pregnancy should discontinue semaglutide at least 2 months before conception due to the 1-week half-life and animal-study fetal harm signals².

Telehealth provider options for GLP-1 monitoring

Several women-focused telehealth providers now manage GLP-1 prescriptions with structured side-effect protocols. For example, Mochi Health offers nutritionist-led titration support and tracks GI symptoms weekly through its app. Form Health pairs board-certified obesity-medicine physicians with registered dietitians and includes lean-mass preservation programming. Found layers behavioral coaching onto GLP-1 prescriptions and screens for contraindications including personal/family thyroid cancer history. PlushCare accepts most commercial insurance for brand-name semaglutide where covered. Each model differs in cost structure, refill cadence, and the depth of female-specific symptom tracking — match the provider to the support level you actually need rather than to a "best" ranking.

Safety: when to call a clinician immediately

Serious adverse events are rare but well-documented. The Wegovy label carries a boxed warning for medullary thyroid carcinoma (MTC) based on rodent studies; semaglutide is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2². A 2023 Diabetes Care pharmacovigilance analysis found a modest signal for thyroid cancer overall with GLP-1 agonists, though absolute risk remains low⁷.

Seek urgent care for: severe persistent abdominal pain radiating to the back (possible pancreatitis), right-upper-quadrant pain with fever or jaundice (gallbladder disease — semaglutide users had 2.6% gallbladder events vs 1.2% placebo in STEP 1¹), persistent vomiting causing dehydration, vision changes in those with diabetic retinopathy, or neck swelling/hoarseness/dysphagia. Hypoglycemia is rare with semaglutide monotherapy but common when combined with insulin or sulfonylureas — symptoms (shakiness, sweating, confusion) require immediate sugar intake and a same-day clinician call.

Pregnancy contraindication is absolute². Animal studies showed fetal malformations and growth restriction at clinically relevant exposures, and the long half-life means inadvertent exposure can persist weeks after the last dose. ACOG's 2021 Obesity in Pregnancy bulletin underscores that obesity-management medications including GLP-1 agonists should be stopped before conception⁶.

Cost and insurance considerations

Cash-pay Wegovy lists at approximately $1,349/month at U.S. retail per the manufacturer's published list price as of 2024². Ozempic (the same molecule labeled for type 2 diabetes) lists at approximately $968/month. Commercial insurance coverage for Wegovy varies — many plans require BMI ≥30 or ≥27 with comorbidity, prior authorization, and documented lifestyle-program participation. Medicare Part D does not currently cover weight-loss indications, though it covers Ozempic for type 2 diabetes. Compounded semaglutide from 503A pharmacies has been widely available at $200-400/month during the FDA-declared shortage, but the FDA removed semaglutide from its shortage list in February 2025, and compounded supply is being phased out. Costs change frequently — confirm current pricing with the dispensing pharmacy or telehealth provider before assuming affordability.

Frequently asked questions

What are the most common semaglutide side effects in women?

Nausea, diarrhea, constipation, vomiting, and abdominal pain are the most frequently reported semaglutide side effects in women, affecting roughly 20-44% of participants in the STEP 1 trial. Most are mild-to-moderate and improve over 4-8 weeks of dose titration.

Does semaglutide affect periods or menstrual cycles?

Some women report cycle changes, heavier or lighter bleeding, and shifts in PMS while on semaglutide. These are not formally listed in the FDA label but are documented in post-marketing reports and case series, likely tied to rapid weight loss altering estrogen and SHBG levels.

Can semaglutide cause hair loss in women?

Hair shedding (telogen effluvium) was reported by approximately 3% of participants in STEP 1 versus 1% on placebo. It is typically diffuse, peaks 3-4 months after starting, and resolves once weight loss stabilizes. Discuss persistent shedding with a clinician.

Does semaglutide interact with birth control pills?

The FDA Wegovy label states that oral contraceptive absorption is not expected to be clinically reduced, but delayed gastric emptying may slow absorption of co-administered oral medications. Vomiting within hours of a pill dose can lower efficacy — backup contraception is often recommended during titration.

Is semaglutide safe during pregnancy?

No. Semaglutide is contraindicated in pregnancy per the FDA label, with animal studies showing fetal harm. Women of reproductive age are advised to discontinue at least 2 months before a planned pregnancy due to the drug's long half-life.

When should I stop semaglutide and call a doctor?

Seek urgent care for severe persistent abdominal pain (possible pancreatitis), right-upper-quadrant pain with fever (gallbladder), neck swelling or hoarseness (rare thyroid risk), severe vomiting with dehydration, or signs of low blood sugar if combined with insulin or sulfonylureas.

Sources

1. Wilding JPH et al., N Engl J Med, 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). https://pubmed.ncbi.nlm.nih.gov/33567185/
2. U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
3. U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209637s029lbl.pdf
4. Sodhi M et al., JAMA, 2023. Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss. https://pubmed.ncbi.nlm.nih.gov/37796527/
5. Rubino DM et al., JAMA, 2022. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). https://pubmed.ncbi.nlm.nih.gov/33755728/
6. American College of Obstetricians and Gynecologists. Obesity in Pregnancy: Practice Bulletin No. 230, 2021. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/06/obesity-in-pregnancy
7. Bezin J et al., Diabetes Care, 2023. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. https://pubmed.ncbi.nlm.nih.gov/36356111/
8. North American Menopause Society. Position Statement on Obesity Management in Midlife Women, 2023. https://www.menopause.org/publications/professional-publications/position-statements-other-reports

Related brands & guides

• Mochi Health — nutritionist-led GLP-1 titration support
• Form Health — obesity-medicine physicians + RD pairing
• Found — behavioral coaching layered onto GLP-1 prescribing
• PlushCare — insurance-friendly brand-name semaglutide

Some brand mentions link to our editorial reviews. Updated 2026-05-29. Reviewed by Dr. Maya Chen, MD, NAMS-CMP.